UTHR
United Therapeutics Corporation · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website unither.com
- Employees(FY) 985
- ISIN US91307C1027
Performance
+0.74%
1W
+13.65%
1M
+22.24%
3M
+18.62%
6M
+20.21%
YTD
+23.29%
1Y
Profile
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Investment Analysis Report: UTHR
Overview
In this investment analysis report, we will delve into a comprehensive analysis of United Therapeutics Corporation (UTHR), a company operating in the Health Technology sector within the Pharmaceuticals: Major industry. We will analyze UTHR's financial health, earnings and revenue growth, profitability, o...
Technical Analysis of UTHR 2024-05-10
Overview:
In analyzing the technical indicators for UTHR over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Analysis:
- Moving Averages (MA): The 5-day Moving Average has been consistently above the Simple...
Recent News & Updates
- 2024-05-10 16:41
- 2024-05-10 11:14
- 2024-05-10 10:58
- 2024-05-09 10:58
- 2024-05-08 23:47
- 2024-05-08 17:15
- 2024-05-08 12:20
- 2024-05-08 09:50
- 2024-05-07 21:50
- 2024-05-07 17:00
- 2024-05-07 11:26
- 2024-05-07 07:27
- 2024-05-07 02:23
- 2024-05-07 02:23
- 2024-05-06 16:43
- 2024-05-06 16:43
- 2024-05-06 12:45
- 2024-05-06 09:45
- 2024-05-06 09:15
- 2024-05-06 02:30
3 Biotech Stocks to Double Your Money in the Next 24 Months(Investorplace)
- 2024-05-06 00:45
- 2024-05-05 21:45
- 2024-05-05 21:15
- 2024-05-04 20:19
- 2024-05-03 19:50
Analyst Report: United Therapeutics Corporation(Morningstar Research)
- 2024-05-03 16:39
- 2024-05-03 14:41
30 Most Profitable Companies with Highest Margins in the World(Insider Monkey)
- 2024-05-02 11:59
- 2024-05-02 11:43
- 2024-05-02 11:35
Page 1 of 9
previousnext